TY  - JOUR
A1  - Müller-von der Grün, Jens
A1  - Rödel, Franz
A1  - Brandts, Christian Hubertus
A1  - Fokas, Emmanouil
A1  - Guckenberger, Matthias
A1  - Rödel, Claus
A1  - Balermpas, Panagiotis
T1  - Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma : where do we stand today and where to go?
T2  - Cancers
N2  - With an increased understanding of the tumor biology of squamous cell carcinoma of the head and neck (SCCHN), targeted therapies have found their way into the clinical treatment routines against this entity. Nevertheless, to date platinum-based cytostatic agents remain the first line choice and targeting the epidermal growth factor-receptor (EGFR) with combined cetuximab and radiation therapy remains the only targeted therapy approved in the curative setting. Investigation of immune checkpoint inhibitors (ICI), such as antibodies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1, resulted in a change of paradigms in oncology and in the first approval of new drugs for treating SCCHN. Nivolumab and pembrolizumab, two anti-PD-1 antibodies, were the first agents shown to improve overall survival for patients with metastatic/recurrent tumors in recent years. Currently, several clinical trials investigate the role of ICI in different therapeutic settings. A robust set of biomarkers will be an inevitable tool for future individualized treatment approaches including radiation dose de-escalation and escalation strategies. This review aims to summarize achieved goals, the current status and future perspectives regarding targeted therapies and ICI in the management of SCCHN.
KW  - immune-checkpoint inhibition
KW  - targeted therapy
KW  - head and neck cancer
KW  - EGFR
KW  - mTOR
KW  - TKI
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50081
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-500812
SN  - 2072-6694
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
VL  - 11
IS  - 4, Art. 472
SP  - 1
EP  - 23
PB  - MDPI
CY  - Basel
ER  -